Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05371093 |
|
Recruitment Status :
Recruiting
First Posted : May 12, 2022
Last Update Posted : April 30, 2024
|
Sponsor:
Kite, A Gilead Company
Information provided by (Responsible Party):
Gilead Sciences ( Kite, A Gilead Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 2030 |
| Estimated Study Completion Date : | October 2030 |